ARL4C might serve as a prognostic factor and a novel therapeutic target for gastric cancer: bioinformatics analyses and biological experiments
Ning Xie(Heilongjiang University of Chinese Medicine), Na Liu(Weifang Medical University), Yongquan Shi(National Clinical Research Center for Digestive Diseases), Lei Dong(North Sichuan Medical University), Ting Yuan(Goethe University Frankfurt), Jian Wu(Henan Academy of Sciences), Kaichun Wu(Xijing Hospital), Zhen Ni(Anhui Provincial Hospital), Jinhai Wang(Second Affiliated Hospital of Xi'an Jiaotong University), Lu Qiao(Second Affiliated Hospital of Xi'an Jiaotong University), Yan Li(Chongqing University), Yuru Bai(China Pharmaceutical University), Bing Xu(Pulmonary Hospital of Lanzhou), Mingzuo Jiang(National Clinical Research Center for Digestive Diseases), Yunfan Bai(The University of Tokyo), Feng Xu(Shandong First Medical University)
Cited by 12
Related Papers
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.7k
Screening for gastric cancer in Asia: current evidence and practice
|The Lancet Oncology|2008|830
Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development
|Science Translational Medicine|2011|772